Genflow Biosciences Share Discussion Threads

[moneymunch] 01/3/2024 07:13

ps Northeast, and how great would it be if Eric's presentation was backed up by some stellar news from Vera and Co from the crucial invivo studies which were expected end of 2023.....looking forward to this coming week.....Gl ;-)

[moneymunch] 01/3/2024 06:39

Nice one Northeast, and Genflow are first to present. Gl ;-)

[northeast14] 29/2/2024 18:35

Virtual investor conference 7th March. Featuring GENFLOW and other US trading company’s in Life Science! Couple of the Big Nasdaq companies also presenting. Some great exposure

[northeast14] 27/2/2024 16:43

The institutions will be here any day also. As per end of last years update on them meeting in London! Q2 was mentioned. Only 5 weeks away

[moneymunch] 27/2/2024 16:03

Lol...and I was planning to release some funds elsewhere to take advantage of the all time low, we've definitely seen the bottom me thinks, and now hopefully a significant rise in volume from those in the know, and pi's who want in for the next flow of positive news. GL :-)

[northeast14] 27/2/2024 15:56

Finally some buyers

[moneymunch] 19/2/2024 08:44

Over 12 months since a crucial patent application, not just for Genflow but a breakthrough for gene therapy and longevity research according to Eric, which could add massive value if awarded. It can take up to 2 years for approval, but the US Patent Office can award within 12 months if accelerated, and so news at anytime which would be truly transformational for all concerned and no doubt be the catalyst for the arrival of institutional investors and increased focus and interest from Major Pharma. Gla :-)

"Genflow has expanded its intellectual property portfolio with a provisional patent application focusing on the SIRT6 gene editing. If granted, this patent could mark a significant breakthrough in gene therapy and longevity research."



1.20230018934

METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688

Applicant GENFLOW BIOSCIENCES SRL

Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

[northeast14] 19/2/2024 07:29

Cyberbub - sorry I ment delivery system patent.

[luckyabbeygale] 18/2/2024 23:57

Longevity is something hardly no one will be able to afford and will miss out on up to an extra thousand years added on to your life if you are not invested in the company that provides it. That is why I invested a 5th of my inheritance into this.

[cyberbub] 18/2/2024 22:27

Thanks all. Which "US institutions" are expected to come on board, is there an announcement somewhere?Has anyone got a reference to the SIRT6 patent grant? The only RNS I could see said that it had been applied for and positively reviewed so far, which is encouraging but I don't know how long they usually take to grant.In Sep 2023 they said that they had cash to March 2025. The more recent grants (IMO) must be spent on specific things, I'm not sure they can go on the central admin costs for example.I'm not trying to sound negative, just trying to see what the real prospects are here. It certainly seems undervalued but what will be the trigger for a re-rate? I've taken a hit on a couple of other shares recently and am keen not to do the same a 3rd time...

[northeast14] 18/2/2024 19:56

Fully funded until 2027. My guess is when the US institutions come onboard there will be a private raise through that. Company actively after more grants. Patent has been approved already and the new patent is to supersede the previous. Great company hugely undervalued. If this was listed solely in America we would be at $1 plus

[marmiesz] 18/2/2024 14:19

There have been hints that a large pharma may get involved. These hints are not overt, but the referencing of Elli Lilly may be one such hint. It may be nothing at all, but they have said, explicitly, they are looking at getting large investors in.Marmie

[cyberbub] 17/2/2024 17:58

Just looking in here. The company's research looks very interesting, but surely they are many years away from making any money. And they probably need to raise money again by early 2025 (the €3M euro grants a few months ago will be targeted at specific work so will be spent). What's the investment case - a takeover by big pharma based on their patent on SIRT61? Has that actually been granted yet does anyone know? Thanks for any info.

[moneymunch] 15/2/2024 07:18

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,494 followers
15h

How we talk about #health and #ageing has changed over the years - terms like "lifespan," while still relevant, have leave gaps.

Newer terms, such as "#healthspan" (the number of years someone is healthy without chronic and debilitating disease), better capture the quality of life we are searching for.

Read about the updated terms here:

#GENF #GENFF #biosciences #longevity

[moneymunch] 14/2/2024 22:51

Could be worse, at least we're not living in Gaza as Israel defends itself....:-(((

[northeast14] 14/2/2024 18:30

It’s endless shares with the seller/sellers. Minimal to no profit selling.

[marmiesz] 14/2/2024 17:31

I see the seller is still here and has been for almost a year! I've no doubt that once we are rid of this then this will re-rate. When, is a moot point but I'm in no rush.Marmie

[northeast14] 14/2/2024 15:03

This will be £1 minimum at takeover in my opinion!! 🚀🚀🚀

[bri15] 14/2/2024 13:11

This could be one of the biggest multi baggers ever seen, given the right news,less than £5 million market cap, cheap as chips this one.

[northeast14] 12/2/2024 19:21

Big sell at 1.45p. Desperate for cash or like you said luckyabbeygale seller could be out finally

[luckyabbeygale] 12/2/2024 14:42

Wow selling at a premium after that huge sell.
This likely means that the seller has been cleared.

[moneymunch] 09/2/2024 07:27

Vera mentioned in her podcast, part of the studies were to establish what tissues should be targetted , including dosage etc, but also higlighted the potential of targeting major organs directly, which presumably includes the liver, which obviously is the focus of Genflow's NASH Clinical trials, and so highly likely Vera's studies could include Sirt6's therapeutic benefit to the liver, and so positive results will be highly significant. Gl ;-)

[moneymunch] 09/2/2024 07:12

Yep, and gene therapy as well, so lots of similar hallmarks, potential and prospects to Genflow.....in the meantime, looking forward to study results from Vera and Co, which could be truly transformational for all concerned, with any luck!!! ;-)

[northeast14] 08/2/2024 21:49

Money,
Lilly at it again. And then Genf posting about it… more crumbs from Eric